Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2012

Jan 29, 2013, 07:00 ET from Boston Scientific Corporation

NATICK, Mass., Jan. 29, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces financial results for the fourth quarter and full year ended December 31, 2012, as well as sales and earnings per share (EPS) guidance for the first quarter and full year 2013. 

Fourth quarter results and recent developments:

  • Reported sales of $1.821 billion, a year-over-year decline of 1 percent on a reported basis and on a constant currency basis excluding divested businesses. Delivered GAAP EPS of $0.04 and adjusted EPS of $0.18. Generated strong operating cash flow of $370 million.
  • Achieved revenue growth of 14 percent and earned the clear number two share position in the U.S. in Neuromodulation, 10 percent in Endoscopy and 9 percent in Peripheral Interventions, all on a constant currency basis.
  • The combined revenue in the countries of Brazil, Russia, India and China grew 35 percent in the quarter, on a constant currency basis.
  • Continued to make progress on strengthening the CRM business with the U.S. launch of the S-ICD System, and the completion of the acquisition of Rhythmia Medical, Inc., a developer of a next-generation mapping and navigation solution for use in electrophysiology procedures.
  • Increased DES revenue 6 percent internationally on a constant currency basis and maintained sequential share in the U.S., despite the year-over-year sales decline.
  • Completed the acquisition of Vessix Vascular, Inc., a developer of a next generation catheter-based renal denervation system for the treatment of uncontrolled hypertension.
  • Repurchased approximately 18 million shares under the 2011 share repurchase authorization.  Separately, the company announces the authorization of a new program to repurchase up to $1 billion of the company's common stock.
  • Approved an expansion of the company's 2011 restructuring program, which is expected to reduce gross annual pre-tax operating expenses by an incremental $100 million to $115 million exiting 2013.

"We are pleased but not satisfied with our improved performance in the quarter," said Mike Mahoney, president and chief executive officer, Boston Scientific. "We continued to enhance our growth portfolio, expand in the emerging markets, and implement operational changes to improve our execution and sharpen our customer focus.  I am confident we are taking the critical steps that are needed to return our company to long-term growth."

Fourth Quarter 2012

Sales for the fourth quarter of 2012 were $1.821 billion, as compared to sales of $1.848 billion for the fourth quarter of 2011, a decrease of 1 percent.  Excluding the impact of foreign currency and sales from divested businesses, sales declined 1 percent as compared to the prior period.

Worldwide sales for the fourth quarter - on a constant currency and as reported basis - were as follows:

Change

Three Months Ended

As Reported

Constant

December 31,

Currency

Currency

in millions

2012

2011

Basis

Basis

Interventional Cardiology

$                 534

$                 594

(10)%

(9)%

Cardiac Rhythm Management

457

482

(5)%

(4)%

Endoscopy

329

304

8 %

10 %

Peripheral Interventions

199

184

8 %

9 %

Urology/Women's Health

130

127

2 %

3 %

Neuromodulation

104

91

14 %

14 %

Electrophysiology

38

36

4 %

5 %

Subtotal Core Businesses

1,791

1,818

(1)%

(1)%

Divested Businesses

30

30

N/A

N/A

Worldwide

$            1,821

$            1,848

(1)%

-   %

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

On a GAAP basis, net income for the fourth quarter of 2012 was $60 million, or $0.04 per share.  These results included divestiture-related net credits, acquisition, restructuring- and litigation-related charges, and amortization expense, of $192 million (after-tax) or $0.14 per share.  Adjusted net income for the fourth quarter of 2012, excluding these net charges, was $252 million, or $0.18 per share.

On a GAAP basis, net income for the fourth quarter of 2011 was $107 million, or $0.07 per share.  These results included acquisition- and divestiture-related net credits, litigation-, and restructuring-related charges, discrete tax items and amortization expense, of $90 million (after-tax) or $0.06 per share.  Adjusted net income for the fourth quarter of 2011, excluding these net charges, was $197 million, or $0.13 per share.

Full Year 2012

Sales for the full year 2012 were $7.249 billion, as compared to sales of $7.622 billion for the full year 2011, a decrease of 5 percent.  Excluding the impact of foreign currency and sales from divested businesses, sales decreased 3 percent as compared to the prior period.

Worldwide sales for the full year - on a constant currency and as reported basis - were as follows:

Change

Year Ended

As Reported

Constant

December 31,

Currency

Currency

in millions

2012

2011

Basis

Basis

Interventional Cardiology

$

2,179

$

2,495

(13)

%

(11)

%

Cardiac Rhythm Management

1,908

2,087

(9)

%

(7)

%

Endoscopy

1,252

1,187

5

%

7

%

Peripheral Interventions

774

731

6

%

8

%

Urology/Women's Health

500

498

-

%

1

%

Neuromodulation

367

336

9

%

9

%

Electrophysiology

147

147

-

%

1

%

Subtotal Core Businesses

7,127

7,481

(5)

%

(3)

%

Divested Businesses

122

141

N/A

N/A

Worldwide

$

7,249

$

7,622

(5)

%

(3)

%

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

On a GAAP basis, net loss for the full year 2012 was $4.068 billion, or $2.89 per share.  Reported results included goodwill and other intangible asset impairment charges, acquisition- and divestiture-related net credits, restructuring- and litigation-related charges, discrete tax items and amortization expense (after-tax) of $5.001 billion, or $3.55 per share.  Adjusted net income for the full year 2012, excluding these net charges, was $933 million, or $0.66 per share.

On a GAAP basis, net income for the full year 2011 was $441 million, or $0.29 per share.  Reported results included goodwill and intangible asset impairment charges; acquisition- and divestiture-related net credits; litigation- and restructuring-related charges; discrete tax items and amortization expense (after-tax) of $577 million, or $0.38 per share.  Adjusted net income for the full year 2011, excluding these net charges, was $1.018 billion, or $0.67 per share.

Expansion of 2011 Restructuring Program

The company also announces an expansion of its 2011 restructuring program (the "Expansion") intended to build on the progress made under that program to strengthen our operational effectiveness and efficiencies and support new growth investments, which we expect will increase shareholder value.  The company estimates that the Expansion will reduce gross annual pre-tax operating expenses by approximately $100 million to $115 million exiting 2013; and that the total 2011 restructuring program, including the Expansion (the "Total Program"), will reduce gross annual pre-tax operating expenses by approximately $340 million to $375 million exiting 2013.  The company expects that a substantial portion of the Total Program savings will be reinvested in targeted areas for future growth, including strategic growth initiatives and emerging markets.  Key activities under the Total Program are expected to be substantially completed by the end of 2013. 

The company anticipates the reduction of 900 to 1,000 positions worldwide through a combination of employee attrition and targeted headcount reductions as a result of the Expansion.  Plans detailing specific employee impacts will be developed for each affected region and business, and the company will work with employee representative bodies where required under local laws.

The company estimates that the implementation of the Expansion will result in total pre-tax charges of approximately $140 million to $160 million, and that approximately $100 million to $120 million of these charges will result in future cash outlays.  The company estimates that the implementation of the Total Program will result in total pre-tax charges of approximately $300 million to $355 million, and that approximately $270 million to $300 million of these charges will result in future cash outlays.

Guidance for First Quarter and Full Year 2013

The company estimates sales for the first quarter of 2013 in a range of $1.740 to $1.815 billion.  The company estimates earnings on a GAAP basis in a range of $0.04 to $0.07 per share.  Adjusted earnings, excluding acquisition- and restructuring-related charges; and amortization expense, are estimated in a range of $0.14 to $0.17 per share. 

The company estimates sales for the full year 2013 in a range of $7.050 to $7.350 billion.  The company estimates earnings on a GAAP basis in a range of $0.29 to $0.37 per share.  Adjusted earnings, excluding divestiture-related net credits, acquisition- and restructuring-related charges; and amortization expense, are estimated in a range of $0.64 to $0.70 per share. 

Conference Call Information

Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. (ET).  The company will webcast the call to interested parties through its website: www.bostonscientific.com.  Please see the website for details on how to access the webcast.  The webcast will be available for approximately one year on the Boston Scientific website.

About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit us at www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP earnings and adjusted earnings for the first quarter and full year 2013; our financial performance; markets for our products and our market share; our business plans; our cost-savings and growth initiatives; our restructuring program activities and expected impact; and our positioning for revenue growth.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions and the market acceptance of those products; markets for our products; expected pricing environment; expected procedural volumes; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this press release.

Use of Non-GAAP Financial Information

A reconciliation of the Company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the Company's use of these non-GAAP financial measures, is included in the exhibits attached to this news release. 

CONTACT:   

Denise Kaigler 508-650-8330 (office) Global Corporate Communications Boston Scientific Corporation media@bsci.com

Steven Campanini 508-652-5740 (office) Media Relations Boston Scientific Corporation media@bsci.com

Michael Campbell 508-650-8023 (office) Investor Relations Boston Scientific Corporation investor_relations@bsci.com

 

BOSTON SCIENTIFIC CORPORATION

CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS

(Unaudited)

Three Months Ended

Year Ended

December 31,

December 31,

in millions, except per share data

2012

2011

2012

2011

Net sales

$

1,821

$

1,848

$

7,249

$

7,622

Cost of products sold

583

660

2,349

2,659

Gross profit

1,238

1,188

4,900

4,963

Operating expenses:

Selling, general and administrative expenses

639

621

2,535

2,487

Research and development expenses

239

230

886

895

Royalty expense

28

33

153

172

Amortization expense

101

96

395

421

Goodwill impairment charges

4,350

697

Intangible asset impairment charges

142

21

Contingent consideration expense (benefit)

4

(12)

(6)

7

Restructuring charges

43

12

136

89

Litigation-related charges

73

48

192

48

Gain on divestiture

(4)

(10)

(15)

(778)

1,123

1,018

8,768

4,059

Operating (loss) income

115

170

(3,868)

904

Other (expense) income:

Interest expense

(64)

(72)

(261)

(281)

Other, net

(1)

2

22

19

(Loss) income before income taxes

50

100

(4,107)

642

Income tax (benefit) expense

(10)

(7)

(39)

201

Net (loss) income

$

60

$

107

$

(4,068)

$

441

Net (loss) income per common share - basic

$

0.04

$

0.07

$

(2.89)

$

0.29

Net (loss) income per common share - assuming dilution

$

0.04

$

0.07

$

(2.89)

$

0.29

Weighted-average shares outstanding

Basic

1,365.9

1,467.6

1,406.7

1,509.3

Assuming dilution

1,375.0

1,479.9

1,406.7

1,519.0

 

BOSTON SCIENTIFIC CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

As of

December 31,

December 31,

in millions, except share and per share data

2012

2011

(Unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$

207

$

267

Trade accounts receivable, net

1,217

1,246

Inventories

884

931

Deferred income taxes

433

458

Prepaid expenses and other current assets

281

203

Total current assets

3,022

3,105

Property, plant and equipment, net

1,564

1,670

Goodwill

5,973

9,761

Other intangible assets, net

6,289

6,473

Other long-term assets

306

281

$

17,154

$

21,290

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Current debt obligations

$

4

$

4

Accounts payable

232

203

Accrued expenses

1,284

1,327

Other current liabilities

252

273

Total current liabilities

1,772

1,807

Long-term debt

4,252

4,257

Deferred income taxes

1,729

1,865

Other long-term liabilities

2,531

2,008

Commitments and contingencies

Stockholders' equity

Preferred stock, $.01 par value - authorized 50,000,000

shares, none issued and outstanding

Common stock, $.01 par value - authorized 2,000,000,000

shares, issued 1,542,347,188 shares as of December 31,

2012 and 1,531,006,390 shares as of December 31, 2011

15

15

Treasury stock, at cost - 186,635,532 as of December 31, 2012

and 81,950,716 shares as of December 31, 2011

(1,092)

(492)

Additional paid-in capital

16,429

16,349

Accumulated deficit

(8,449)

(4,381)

Other stockholders' deficit

(33)

(138)

Total stockholders' equity

6,870

11,353

$

17,154

$

21,290

 

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS

(Unaudited)

Three Months Ended December 31,

2012

2011

Net

Impact

Impact

(loss)

per diluted

Net

per diluted

in millions, except per share data

income

share

income

share

GAAP net (loss) income

$

60

$

0.04

$

107

$

0.07

Non-GAAP adjustments:

Acquisition-related net (credits) charges

1

(9)

(0.01)

Divestiture-related net credits

(2)

(9)

(0.01)

Restructuring-related charges

47

0.04

14

0.01

Litigation-related charges

46

0.03

30

0.02

Discrete tax items

(5)

Amortization expense

100

0.07

69

0.05

Adjusted net income

$

252

$

0.18

$

197

$

0.13

Year Ended December 31,

2012

2011

Net

Impact

Impact

(loss)

per diluted

Net

per diluted

in millions, except per share data

income

share

income

share

GAAP net (loss) income

$

(4,068)

$

(2.89)

$

441

$

0.29

Non-GAAP adjustments:

Goodwill impairment charges

4,327

3.06

*

697

0.46

Intangible asset impairment charges

119

0.09

*

16

0.01

Acquisition-related net credits

(30)

(0.02)

*

(27)

(0.02)

Divestiture-related net credits

(6)

*

(542)

(0.35)

Restructuring-related charges

122

0.09

*

90

0.06

Litigation-related charges

118

0.08

*

30

0.02

Discrete tax items

2

*

(27)

(0.02)

Amortization expense

349

0.25

*

340

0.22

Adjusted net income

$

933

$

0.66

$

1,018

$

0.67

* Assumes dilution of 7.7 million shares for the year ended December 31, 2012 for all or a portion of these non-GAAP adjustments.

An explanation of the Company's use of these non-GAAP financial measures is provided at the end of this document.

 

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS (CONT.)

(Unaudited)

Three Months Ended

Year Ended

in millions

December 31,

December 31,

2012

2011

2012

2011

Goodwill impairment charges:

Goodwill impairment charges

$

4,350

$

697

Income tax benefit (a)

(23)

Goodwill impairment charges, net of tax

$

4,327

$

697

Intangible asset impairment charges:

Intangible asset impairment charges

$

142

$

21

Income tax benefit (a)

(23)

(5)

Intangible asset impairment charges, net of tax

$

119

$

16

Acquisition-related charges (credits):

Contingent consideration (benefit) expense

$

4

$

(12)

$

(6)

$

7

Acquisition-related costs (credits) (b)

(2)

1

4

3

Inventory step-up adjustment (c)

1

3

Gain on previously held investments (d)

(39)

(38)

2

(10)

(41)

(25)

Income tax (expense) benefit (a)

(1)

1

11

(2)

Acquisition-related net (credits) charges, net of tax

$

1

$

(9)

$

(30)

$

(27)

Divestiture-related net credits:

Gain on divestiture

$

(4)

$

(10)

$

(15)

$

(778)

Divestiture-related costs (c)

$

2

$

1

$

6

5

(2)

(9)

(9)

(773)

Income tax expense (a)

3

231

Divestiture-related net credits, net of tax

$

(2)

$

(9)

$

(6)

$

(542)

Restructuring-related charges:

Restructuring charges

$

43

$

12

$

136

$

89

Restructuring-related charges (e)

9

8

24

40

52

20

160

129

Income tax benefit (a)

(5)

(6)

(38)

(39)

Restructuring-related charges, net of tax

$

47

$

14

$

122

$

90

Litigation-related net charges:

Litigation-related net charges

$

73

48

$

192

48

Income tax benefit (a)

(27)

(18)

(74)

(18)

Litigation-related net charges, net of tax

$

46

30

$

118

$

30

Discrete tax items:

Income tax expense (benefit) (a)

$

(5)

$

2

$

(27)

Amortization expense:

Amortization expense

$

101

$

96

$

395

$

421

Income tax benefit (a)

(1)

(27)

(46)

(81)

Amortization expense, net of tax

$

100

$

69

$

349

$

340

(a)  

Amounts are tax affected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with  FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."

(b)  

In the fourth quarter of 2012, recorded a $1 million to selling, general and administrative expenses and a $3 million benefit to research and development expenses.  In 2012, recorded $7 million to selling, general and administrative expenses and $3 million benefit to research and development expenses

(c)  

Recorded to cost of products sold.

(d)  

Recorded to other, net.

(e)  

In the fourth quarter of 2012, recorded $1 million to cost of products sold and $8 million to selling, general and administrative expenses. In the fourth quarter of 2011, recorded $8 million to cost of products sold. In 2012, recorded $8 million to cost of products sold and $16 million to selling, general and administrative expenses. In 2011, recorded $35 million to cost of products sold and $5 million to selling, general and administrative expenses.

An explanation of the Company's use of these non-GAAP financial measures is provided at the end of this document.

 

BOSTON SCIENTIFIC CORPORATION

WORLDWIDE SALES

(Unaudited)

Change

Three Months Ended

As Reported

Constant

December 31,

Currency

Currency

in millions

2012

2011

Basis

Basis

(restated)

*

United States

$

924

$

957

(3)

%

(3)

%

EMEA

396

409

(3)

%

(1)

%

Japan

236

247

(4)

%

1

%

Inter-Continental

235

205

15

%

14

%

International

867

861

1

%

3

%

Subtotal Core Businesses

1,791

1,818

(1)

%

(1)

%

Divested Businesses

30

30

N/A

N/A

Worldwide

$

1,821

$

1,848

(1)

%

%

 

Change

Three Months Ended

As Reported

Constant

December 31,

Currency

Currency

in millions

2012

2011

Basis

Basis

Interventional Cardiology

$                 534

$                 594

(10)%

(9)%

Cardiac Rhythm Management

457

482

(5)%

(4)%

Endoscopy

329

304

8 %

10 %

Peripheral Interventions

199

184

8 %

9 %

Urology/Women's Health

130

127

2 %

3 %

Neuromodulation

104

91

14 %

14 %

Electrophysiology

38

36

4 %

5 %

Subtotal Core Businesses

1,791

1,818

(1)%

(1)%

Divested Businesses

30

30

N/A

N/A

Worldwide

$            1,821

$            1,848

(1)%

-   %

* We have restated prior year regional detail to conform to current year presentation.

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

An explanation of the Company's use of these non-GAAP financial measures is provided at the end of this document.

 

BOSTON SCIENTIFIC CORPORATION

WORLDWIDE SALES

(Unaudited)

Change

Year Ended

As Reported

Constant

December 31,

Currency

Currency

in millions

2012

2011

Basis

Basis

(restated)

*

United States

$

3,756

$

4,010

(6)

%

(6)

%

EMEA

1,568

1,721

(9)

%

(3)

%

Japan

931

951

(2)

%

(2)

%

Inter-Continental

872

799

9

%

11

%

International

3,371

3,471

(3)

%

1

%

Subtotal Core Businesses

7,127

7,481

(5)

%

(3)

%

Divested Businesses

122

141

N/A

N/A

Worldwide

$

7,249

$

7,622

(5)

%

(3)

%

 

Change

Year Ended

As Reported

Constant

December 31,

Currency

Currency

in millions

2012

2011

Basis

Basis

Interventional Cardiology

$

2,179

$

2,495

(13)

%

(11)

%

Cardiac Rhythm Management

1,908

2,087

(9)

%

(7)

%

Endoscopy

1,252

1,187

5

%

7

%

Peripheral Interventions

774

731

6

%

8

%

Urology/Women's Health

500

498

%

1

%

Neuromodulation

367

336

9

%

9

%

Electrophysiology

147

147

%

1

%

Subtotal Core Businesses

7,127

7,481

(5)

%

(3)

%

Divested Businesses

122

141

N/A

N/A

Worldwide

$

7,249

$

7,622

(5)

%

(3)

%

* We have restated prior year regional detail to conform to current year presentation.

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

An explanation of the Company's use of these non-GAAP financial measures is provided at the end of this document.

 

BOSTON SCIENTIFIC CORPORATION

NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS

(Unaudited)

Q4 2012 Net Sales as compared to Q4 2011

Change

Estimated

As Reported

Constant

Impact of

Currency

Currency

Foreign

in millions

Basis

Basis

Currency

United States

$

(33)

$

(33)

EMEA

(13)

(5)

$

(8)

Japan

(11)

1

(12)

Inter-Continental

30

28

2

International

6

24

(18)

Subtotal Core Businesses

(27)

(9)

(18)

Divested Businesses

Worldwide

$

(27)

$

(9)

$

(18)

Q4 2012 Net Sales as compared to Q4 2011

Change

Estimated

As Reported

Constant

Impact of

Currency

Currency

Foreign

in millions

Basis

Basis

Currency

Interventional Cardiology

$

(60)

$

(53)

$

(7)

Cardiac Rhythm Management

(25)

(20)

(5)

Endoscopy

25

29

(4)

Peripheral Interventions

15

17

(2)

Urology/Women's Health

3

4

(1)

Neuromodulation

13

12

1

Electrophysiology

2

2

Subtotal Core Businesses

(27)

(9)

(18)

Divested Businesses

Worldwide

$

(27)

$

(9)

$

(18)

An explanation of the Company's use of these non-GAAP financial measures is provided at the end of this document.

 

BOSTON SCIENTIFIC CORPORATION

NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS

(Unaudited)

Q4 2012 YTD Net Sales as compared to Q4 2011 YTD

Change

Estimated

As Reported

Constant

Impact of

Currency

Currency

Foreign

in millions

Basis

Basis

Currency

United States

$

(254)

$

(254)

EMEA

(153)

(48)

$

(105)

Japan

(20)

(16)

(4)

Inter-Continental

73

86

(13)

International

(100)

22

(122)

Subtotal Core Businesses

(354)

(232)

(122)

Divested Businesses

(19)

(18)

(1)

Worldwide

$

(373)

$

(250)

$

(123)

Q4 2012 YTD Net Sales as compared to Q4 2011 YTD

Change

Estimated

As Reported

Constant

Impact of

Currency

Currency

Foreign

in millions

Basis

Basis

Currency

Interventional Cardiology

$

(316)

$

(266)

$

(50)

Cardiac Rhythm Management

(179)

(145)

(34)

Endoscopy

65

84

(19)

Peripheral Interventions

43

56

(13)

Urology/Women's Health

2

5

(3)

Neuromodulation

31

32

(1)

Electrophysiology

2

(2)

Subtotal Core Businesses

(354)

(232)

(122)

Divested Businesses

(19)

(18)

(1)

Worldwide

$

(373)

$

(250)

$

(123)

An explanation of the Company's use of these non-GAAP financial measures is provided at the end of this document.

 

BOSTON SCIENTIFIC CORPORATION

WORLDWIDE CARDIAC RHYTHM MANAGEMENT AND CORONARY STENT SYSTEM SALES

(Unaudited)

Three Months Ended December 31

in millions

U.S.

International

Worldwide

Q4 2012

Q4 2011

Q4 2012

Q4 2011

Q4 2012

Q4 2011

Defibrillator systems

$

204

$

214

$

126

$

134

$

330

$

348

Pacemaker systems

61

64

66

70

127

134

Total CRM products

$

265

$

278

$

192

$

204

$

457

$

482

in millions

U.S.

International

Worldwide

Q4 2012

Q4 2011

Q4 2012

Q4 2011

Q4 2012

Q4 2011

Drug-eluting stent systems

$

118

$

168

$

194

$

188

*

$

312

$

356

Bare-metal stent systems

6

7

15

18

21

25

Total coronary stent systems

$

124

$

175

$

209

$

206

$

333

$

381

Year Ended December 31

in millions

U.S.

International

Worldwide

2012

2011

2012

2011

2012

2011

Defibrillator systems

$

858

$

949

$

521

$

569

$

1,379

$

1,518

Pacemaker systems

256

279

273

290

529

569

Total CRM products

$

1,114

$

1,228

$

794

$

859

$

1,908

$

2,087

in millions

U.S.

International

Worldwide

2012

2011

2012

2011

2012

2011

Drug-eluting stent systems

$

557